EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Statins and uterine fibroids: Potential for a novel therapeutic approach

D M C S Jayasundara iD, I A Jayawardane iD, T D K M Jayasingha iD, S De Silva Weliange iD, N M C L Nishshanka iD

International Journal of Gynecology & Obstetrics · 2026-05 · 173 (2) · 654-667

DOI: 10.1002/ijgo.70664 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 24.11.2025. Verfasst von D M C S Jayasundara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. Hauptthemen laut MEDLINE: Leiomyoma, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Uterine Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Uterine fibroids are the most common benign gynecological tumors, affecting up to 70% of women. Only 25% of women with uterine fibroids are symptomatic. Despite the significant clinical burden, no satisfactory long‐term medical therapy is currently available. Definitive management often warrants surgery, which might result in significant morbidity and economic burden. Therefore, there is a growing need for novel and effective medical therapy. Statins have shown broad‐reaching pleiotropic effects on uterine fibroids, potentially inhibiting growth, reducing the incidence, and alleviating the symptoms.

Objectives

The current study aims to explore the pathophysiological mechanisms and clinical effects of statins on uterine fibroids. Search Strategy We retrieved relevant studies from PubMed, Cochrane Library, Embase, and ScienceDirect, published up to January 3, 2025. The study selection process was conducted using the semi‐automated tool Rayyan. Selection Criteria Full‐text articles of randomized controlled trials (RCTs), case–control studies, cross‐sectional studies, cohort studies, case series, and experimental studies in the English language that describe the pathophysiological mechanisms and clinical effects of statins on uterine fibroids were included. Review articles or book chapters were excluded. Data Collection and Analysis Key study characteristics were organized into predefined tables concerning outcome measures: pathophysiological mechanisms and clinical effects. Data synthesis involved a thematic analysis. A meta‐analysis was not performed due to study heterogeneity. Study quality assessment was conducted using the Newcastle‐Ottawa Scale (NOS), the Cochrane risk‐of‐bias (RoB1) tool, and the Quality Assessment Tool for In Vitro Studies (QUIN Tool). Main Results We included 13 studies screening 574 studies from four databases, where eight were laboratory‐based experimental studies, four were clinical studies, and one provided data on both. Quality assessment graded the studies as moderate to high quality. Statins exhibited diverse pharmacodynamic effects on leiomyoma cells, including a reduction in estrogen receptor‐α (ER‐α) levels and activity, alterations in intracellular signaling pathways that regulate cell proliferation, a decrease in extracellular matrix (ECM) production, induction of apoptosis, and improvements in altered cellular mechanotransduction, as well as changes in stemness markers. Clinical studies have demonstrated that statins have a significant impact on reducing fibroid volume and alleviating symptoms associated with fibroids.

Conclusion

Statins have demonstrated anti‐proliferative and pro‐apoptotic effects on uterine fibroids, resulting in symptomatic improvement and reduction in fibroid volume in clinical studies. However, given the paucity of evidence, it is challenging to conclude on the comparative efficacy, the most appropriate type of statin, the optimal dosing regimen, and the treatment duration, thereby creating a potential research gap. Therefore, we recommend well‐planned prospective studies to establish the role of statins in the management of uterine fibroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeiomyomaHydroxymethylglutaryl-CoA Reductase InhibitorsUterine NeoplasmsHumansFemale

Stichwörter der Autor:innen

statinssystematic reviewuterine fibroid

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
  • De Soysa Maternity Hospital, Colombo, Sri Lanka.
  • Department of Community Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
  • Ministry of Health, Colombo, Sri Lanka.

ORCID-Profile: D M C S Jayasundara, I A Jayawardane, T D K M Jayasingha, S De Silva Weliange, N M C L Nishshanka

Zitieren

APA

Jayasundara, D. M. C. S., Jayawardane, I. A., Jayasingha, T. D. K. M., De Silva Weliange, S., & Nishshanka, N. M. C. L. (2026). Statins and uterine fibroids: Potential for a novel therapeutic approach. International Journal of Gynecology & Obstetrics, 173(2), 654-667. https://doi.org/10.1002/ijgo.70664

Vancouver

Jayasundara DMCS, Jayawardane IA, Jayasingha TDKM, De Silva Weliange S, Nishshanka NMCL. Statins and uterine fibroids: Potential for a novel therapeutic approach. International Journal of Gynecology & Obstetrics. 2026;173(2):654-667. doi:10.1002/ijgo.70664

BibTeX
@article{Jayasundara2026,
  author = {Jayasundara, D M C S and Jayawardane, I A and Jayasingha, T D K M and De Silva Weliange, S and Nishshanka, N M C L},
  title = {Statins and uterine fibroids: Potential for a novel therapeutic approach},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  volume = {173},
  number = {2},
  pages = {654--667},
  doi = {10.1002/ijgo.70664}
}
Kostenlos starten →